Increased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?
作者信息
Boerenkamp Lara S, Pothast Cilia R, Dijkland Romy C, van Dijk Kayleigh, van Gorkom Gwendolyn N Y, van Loo Inge H M, Wieten Lotte, Halkes Constantijn J M, Heemskerk Mirjam H M, Van Elssen Catharina H M J
机构信息
Department of Internal Medicine, Division of Hematology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands.
Experimental Hematology, Leiden University Medical Center, Leiden, The Netherlands.
出版信息
Am J Hematol. 2022 Dec;97(12):E457-E461. doi: 10.1002/ajh.26729. Epub 2022 Sep 24.
Abstract
摘要
相似文献
1
Increased CD8 T-cell immunity after COVID-19 vaccination in lymphoid malignancy patients lacking adequate humoral response: An immune compensation mechanism?在缺乏足够体液反应的淋巴系统恶性肿瘤患者中，新冠病毒疫苗接种后CD8 T细胞免疫增强：一种免疫补偿机制？
Am J Hematol. 2022 Dec;97(12):E457-E461. doi: 10.1002/ajh.26729. Epub 2022 Sep 24.
2
Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.在真实环境中评估灭活 COVID-19 疫苗诱导的 SARS-CoV-2 特异性体液和细胞免疫应答的特征。
Front Immunol. 2021 Dec 22;12:802858. doi: 10.3389/fimmu.2021.802858. eCollection 2021.
3
Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.CoronaVac 疫苗接种预防 COVID-19 后 12 个月内体液和细胞免疫应答的状况。
mBio. 2022 Jun 28;13(3):e0018122. doi: 10.1128/mbio.00181-22. Epub 2022 Apr 27.
4
T follicular helper cells in the humoral immune response to SARS-CoV-2 infection and vaccination.T 滤泡辅助细胞在 SARS-CoV-2 感染和疫苗接种的体液免疫反应中的作用。
J Leukoc Biol. 2022 Feb;111(2):355-365. doi: 10.1002/JLB.5MR0821-464R. Epub 2021 Nov 3.
5
Induction of High Levels of Specific Humoral and Cellular Responses to SARS-CoV-2 After the Administration of Covid-19 mRNA Vaccines Requires Several Days.接种 COVID-19 mRNA 疫苗后，需要数天才能诱导针对 SARS-CoV-2 的高特异性体液和细胞反应。
Front Immunol. 2021 Oct 4;12:726960. doi: 10.3389/fimmu.2021.726960. eCollection 2021.
6
Protective Immunity of COVID-19 Vaccination with ChAdOx1 nCoV-19 Following Previous SARS-CoV-2 Infection: A Humoral and Cellular Investigation.先前感染 SARS-CoV-2 后接种 ChAdOx1 nCoV-19 对 COVID-19 的保护免疫：体液和细胞研究。
Viruses. 2022 Aug 30;14(9):1916. doi: 10.3390/v14091916.
7
A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.一种双抗原自扩增 RNA SARS-CoV-2 疫苗可诱导强烈的体液和细胞免疫应答，并通过 T 细胞介导的免疫来预防 SARS-CoV-2 变体。
Mol Ther. 2022 Sep 7;30(9):2968-2983. doi: 10.1016/j.ymthe.2022.04.014. Epub 2022 Apr 20.
8
Dominant Antiviral CD8 T Cell Responses Empower Prophylactic Antibody-Eliciting Vaccines Against Cytomegalovirus.优势抗病毒 CD8 T 细胞反应增强了针对巨细胞病毒的预防性抗体诱导疫苗。
Front Immunol. 2022 Jan 27;13:680559. doi: 10.3389/fimmu.2022.680559. eCollection 2022.
9
Immunogenicity of Anti-SARS-CoV-2 Vaccines in Common Variable Immunodeficiency.常见变异性免疫缺陷患者中抗 SARS-CoV-2 疫苗的免疫原性。
J Clin Immunol. 2022 Feb;42(2):240-252. doi: 10.1007/s10875-021-01174-5. Epub 2021 Nov 17.
10
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.利妥昔单抗治疗患者的新型冠状病毒2型疫苗接种：体液免疫受损但细胞免疫反应可诱导的证据
Ann Rheum Dis. 2021 Oct;80(10):1355-1356. doi: 10.1136/annrheumdis-2021-220408. Epub 2021 May 6.
引用本文的文献
1
Increasing the odds: antibody-mediated delivery of two distinct immunogenic T-cell epitopes with one antibody.提高几率：用一种抗体介导递送两种不同的免疫原性T细胞表位。
Oncoimmunology. 2025 Dec;14(1):2508050. doi: 10.1080/2162402X.2025.2508050. Epub 2025 May 27.
2
Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.甘露糖修饰的脂质磷酸钙纳米颗粒疫苗通过调节肿瘤微环境增强抗肿瘤免疫反应。
J Funct Biomater. 2024 Aug 16;15(8):229. doi: 10.3390/jfb15080229.
3
Immunogenicity of the 13-Valent Pneumococcal Conjugated Vaccine Followed by the 23-Valent Polysaccharide Vaccine in Chronic Lymphocytic Leukemia.13价肺炎球菌结合疫苗后接种23价多糖疫苗在慢性淋巴细胞白血病中的免疫原性
Vaccines (Basel). 2023 Jul 4;11(7):1201. doi: 10.3390/vaccines11071201.
4
Fourth mRNA COVID-19 vaccination in immunocompromised patients with haematological malignancies (COBRA KAI): a cohort study.血液系统恶性肿瘤免疫功能低下患者的第四次新冠病毒mRNA疫苗接种（COBRA KAI）：一项队列研究
EClinicalMedicine. 2023 Jul;61:102040. doi: 10.1016/j.eclinm.2023.102040. Epub 2023 Jun 15.
5
SARS-CoV-2 vaccine-induced humoral and cellular immunity in patients with hematologic malignancies.SARS-CoV-2 疫苗在血液系统恶性肿瘤患者中诱导的体液和细胞免疫。
Semin Hematol. 2022 Oct;59(4):192-197. doi: 10.1053/j.seminhematol.2022.11.001. Epub 2022 Nov 19.
Zotero 插件